James Dentzer, Curis CEO
Patient death triggers a second clinical hold for Curis as FDA seeks more data
After a patient died in a Phase I/IIa clinical trial for leukemia, the FDA has imposed an additional partial hold on Curis’ ongoing Phase I …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
